The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Nicoli, Francesco ^a   Finessi, Valentina ^a   Sicurella, Mariaconcetta ^a,b   Rizzotto, Lara ^c   Gallerani, Eleonora ^a   Destro, Federica ^a,b   Cafaro, Aurelio ^d   Marconi, Peggy ^a   Caputo, Antonella ^b   Ensoli, Barbara ^d   Gavioli, Riccardo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGENICITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CD8+ T LYMPHOCYTE; CELL KINETICS; CELL LOSS; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; EX VIVO STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VIVO STUDY; INFECTION CONTROL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHLOROCEBUS AETHIOPS; CYTOTOXIC T LYMPHOCYTE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; KINETICS; LYMPHOCYTE ACTIVATION; VERO CELL LINE; VIROLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; KINETICS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VERO CELLS;

EID: 84892428218     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077746     Document Type: Article

References (87)

1. UNAIDS (2012) UNAIDS World AIDS Day Report |.
2. Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T et al. (2011) CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol 186: 2106-2116. doi:10.4049/jimmunol.1002000. PubMed: 21257970.
3. Haas A, Zimmermann K, Oxenius A (2011) Antigen-dependent and - independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. J Virol 85: 12102-12113. doi:10.1128/JVI.05607-11. PubMed: 21849433.
4. Peretz Y, He Z, Shi Y, Yassine-Diab B, Goulet JP et al. (2012) CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLOS Pathog 8: e1002840. PubMed: 22916009.
5. Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM et al. (1986) The trans-activator gene of HTLV-III is essential for virus replication. Nature 320: 367-371. doi:10.1038/320367a0. PubMed: 3007995.
6. Ott M, Emiliani S, Van Lint C, Herbein G, Lovett J et al. (1997) Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 275: 1481-1485. doi:10.1126/science.275.5305.1481. PubMed: 9045614.
7. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L et al. (1997) Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci U S A 94: 8116-8120. doi:10.1073/pnas.94.15.8116. PubMed: 9223324.
8. Arya SK, Guo C, Josephs SF, Wong-Staal F (1985) Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229: 69-73. doi:10.1126/science.2990040. PubMed: 2990040.
9. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B (1997) HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11: 1421-1431. doi: 10.1097/00002030-199712000-00006. PubMed: 9342064.
10. Rayne F, Debaisieux S, Yezid H, Lin YL, Mettling C et al. (2010) Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J 29: 1348-1362. doi:10.1038/emboj.2010.32. PubMed: 20224549.
11. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F (1990) Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345: 84-86. doi: 10.1038/345084a0. PubMed: 2184372.
12. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R et al. (1993) Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67: 277-287. PubMed: 8416373.
13. Mediouni S, Darque A, Baillat G, Ravaux I, Dhiver C et al. (2012) Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. Infect Disord Drug Targets 12: 81-86. doi:10.2174/187152612798994939. PubMed: 22280310.
14. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S et al. (1994) Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 371: 674-680. doi: 10.1038/371674a0. PubMed: 7935812.
15. Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Cossut Pavone et al. (2009) HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol 182: 2888-2897. doi: 10.4049/jimmunol.0711406. PubMed: 19234184.
16. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F et al. (2002) Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 168: 197-206. PubMed: 11751963.
17. Secchiero P, Zella D, Curreli S, Mirandola P, Capitani S et al. (2000) Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication. Proc Natl Acad Sci U S A 97: 14620-14625. doi:10.1073/pnas.011512398. PubMed: 11114167.
18. Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M et al. (1995) The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood 86: 3823-3834. PubMed: 7579350.
19. Kwon HS, Brent MM, Getachew R, Jayakumar P, Chen LF et al. (2008) Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3: 158-167. doi:10.1016/j.chom.2008.02.002. PubMed: 18329615.
20. Gavioli R, Gallerani E, Fortini C, Fabris M, Bottoni A et al. (2004) HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 173: 3838-3843. PubMed: 15356131.
21. Buonaguro L, Buonaguro FM, Giraldo G, Ensoli B (1994) The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. J Virol 68: 2677-2682. PubMed: 8139045.
22. Buonaguro L, Barillari G, Chang HK, Bohan CA, Kao V et al. (1992) Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 66: 7159-7167. PubMed: 1279199.
23. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M et al. (2006) Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 211: 81-92. doi:10.1111/j.0105-2896.2006.00382.x. PubMed: 16824119.
24. Bellino S, Francavilla V, Longo O, Tripiciano A, Paniccia G et al. (2009) Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials 4: 195-204. PubMed: 20028332.
25. Tognon M, Manservigi R, Sebastiani A, Bragliani G, Busin M et al. (1985) Analysis of HSV isolated from patients with unilateral and bilateral herpetic keratitis. Int Ophthalmol 8: 13-18. doi:10.1007/BF00136456. PubMed: 2991155.
26. Krisky DM, Marconi PC, Oligino TJ, Rouse RJ, Fink DJ et al. (1998) Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther 5: 1517-1530. doi:10.1038/sj.gt.3300755. PubMed: 9930305.
27. Krisky DM, Marconi PC, Oligino T, Rouse RJ, Fink DJ et al. (1997) Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther 4: 1120-1125. doi:10.1038/sj.gt.3300497. PubMed: 9415320.
28. Fraefel C, Marconi P, Epstein AL (2011) Herpes simplex virus type 1- derived recombinant and amplicon vectors. Methods Mol Biol 737: 303-343. doi:10.1007/978-1-61779-095-9-13. PubMed: 21590403.
29. Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E et al. (2008) The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. Vaccine 26: 727-737. doi:10.1016/j.vaccine. 2007.11.040. PubMed: 18096278.
30. Fortin JF, Barat C, Beauséjour Y, Barbeau B, Tremblay MJ (2004) Hyper-responsiveness to stimulation of human immunodeficiency virus-infected CD4+ T cells requires Nef and Tat virus gene products and results from higher NFAT, NF-kappaB, and AP-1 induction. J Biol Chem 279: 39520-39531. doi:10.1074/jbc.M407477200. PubMed: 15258149.
31. Cellini S, Fortini C, Gallerani E, Destro F, Cofano EB et al. (2008) Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice. Virol J 5: 81. doi:10.1186/1743-422X-5-81. PubMed: 18625037.
32. Yang TC, Dayball K, Wan YH, Bramson J (2003) Detailed analysis of the CD8+ T-cell response following adenovirus vaccination. J Virol 77: 13407-13411. doi:10.1128/JVI.77.24.13407-13411.2003. PubMed: 14645597.
33. Krebs P, Scandella E, Odermatt B, Ludewig B (2005) Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus. J Immunol 174: 4559-4566. PubMed: 15814677.
34. Bachmann MF, Wolint P, Schwarz K, Jäger P, Oxenius A (2005) Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol 175: 4686-4696. PubMed: 16177116.
35. Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE et al. (2009) Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol 83: 11876-11889. doi:10.1128/JVI.01153-09. PubMed: 19726501.
36. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D et al. (2007) Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473-2485. doi:10.1084/jem.20070784. PubMed: 17893201.
37. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789. doi:10.1182/blood-2005-12-4818. PubMed: 16467198.
38. Chew T, Taylor KE, Mossman KL (2009) Innate and adaptive immune responses to herpes simplex virus. Viruses 1: 979-1002. doi:10.3390/v1030979. PubMed: 21994578.
39. Decman V, Freeman ML, Kinchington PR, Hendricks RL (2005) Immune control of HSV-1 latency. Viral Immunol 18: 466-473. doi: 10.1089/vim.2005.18.466. PubMed: 16212525.
40. Koelle DM, Corey L (2003) Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 16: 96-113. doi:10.1128/CMR.16.1.96-113.2003. PubMed: 12525427.
41. Dabrowska A, Kim N, Aldovini A (2008) Tat-induced FOXO3a is a key mediator of apoptosis in HIV-1-infected human CD4+ T lymphocytes. J Immunol 181: 8460-8477. PubMed: 19050264.
42. Minami R, Yamamoto M, Takahama S, Miyamura T, Watanabe H et al. (2006) RCAS1 induced by HIV-Tat is involved in the apoptosis of HIV-1 infected and uninfected CD4+ T cells. Cell Immunol 243: 41-47. doi: 10.1016/j.cellimm.2006. 11.003. PubMed: 17250817.
43. Varbanov M, Espert L, Biard-Piechaczyk M (2006) Mechanisms of CD4 T-cell depletion triggered by HIV-1 viral proteins. AIDS Res 8: 221-236. PubMed: 17219737.
44. Huang L, Li CJ, Pardee AB (1997) Human immunodeficiency virus type 1 TAT protein activates B lymphocytes. Biochem Biophys Res Commun 237: 461-464. doi:10.1006/bbrc.1997.7162. PubMed: 9268734.
45. Colombrino E, Rossi E, Ballon G, Terrin L, Indraccolo S et al. (2004) Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells. Exp Cell Res 295: 539-548. doi:10.1016/j.yexcr.2004.01.018. PubMed: 15093750.
46. Peruzzi F (2006) The multiple functions of HIV-1 Tat: proliferation versus apoptosis. Front Biosci 11: 708-717. doi:10.2741/1829. PubMed: 16146763.
47. Obar JJ, Lefrançois L (2010) Early signals during CD8 T cell priming regulate the generation of central memory cells. J Immunol 185: 263-272. doi:10.4049/jimmunol.1000492. PubMed: 20519649.
48. Mohr E, Cunningham AF, Toellner KM, Bobat S, Coughlan RE et al. (2010) IFN-{gamma} produced by CD8 T cells induces T-bet-dependent and -independent class switching in B cells in responses to alum-precipitated protein vaccine. Proc Natl Acad Sci U S A 107: 17292-17297. doi:10.1073/pnas.1004879107. PubMed: 20855629.
49. Voltan R, Castaldello A, Brocca-Cofano E, De Michele R, Triulzi C et al. (2009) Priming with a very low dose of DNA complexed with cationic block copolymers followed by protein boost elicits broad and longlasting antigen-specific humoral and cellular responses in mice. Vaccine 27: 4498-4507. doi:10.1016/j.vaccine.2009.05.031. PubMed: 19450649.
50. Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F et al. (2006) Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 20: 2245-2261. doi:10.1097/QAD.0b013e3280112cd1. PubMed: 17117011.
51. Richardson MW, Mirchandani J, Duong J, Grimaldo S, Kocieda V et al. (2003) Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 57: 4-14. doi:10.1016/S0753-3322(02)00327-X. PubMed: 12642031.
52. Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A et al. (2005) The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 191: 1321-1324. doi: 10.1086/428909. PubMed: 15776379.
53. Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V et al. (2010) Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLOS ONE 5: e13540. doi:10.1371/journal.pone.0013540. PubMed: 21085635.
54. Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM et al. (2000) Early programming of T cell populations responding to bacterial infection. J Immunol 165: 6833-6839. PubMed: 11120806.
55. Badovinac VP, Porter BB, Harty JT (2004) CD8+ T cell contraction is controlled by early inflammation. Nat Immunol 5: 809-817. doi:10.1038/ ni1098. PubMed: 15247915.
56. Leifert JA, Holler PD, Harkins S, Kranz DM, Whitton JL (2003) The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes. Gene Ther 10: 2067-2073. doi: 10.1038/sj.gt.3302115. PubMed: 14595379.
57. Demarchi F, Gutierrez MI, Giacca M (1999) Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. J Virol 73: 7080-7086. PubMed: 10400814.
58. Fiume G, Vecchio E, De Laurentiis A, Trimboli F, Palmieri C et al. (2012) Human immunodeficiency virus-1 Tat activates NF-kappaB via physical interaction with IkappaB-alpha and p65. Nucleic Acids Res 40: 3548-3562. doi:10.1093/nar/gkr1224. PubMed: 22187158.
59. Song J, So T, Croft M (2008) Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. J Immunol 180: 7240-7248. PubMed: 18490723.
60. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J et al. (1998) Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci U S A 95: 3851-3856. doi:10.1073/pnas.95.7.3851. PubMed: 9520456.
61. Ambrosino C, Ruocco MR, Chen X, Mallardo M, Baudi F et al. (1997) HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem 272: 14883-14892. doi:10.1074/jbc.272.23. 14883. PubMed: 9169458.
62. Klenerman P, Cerundolo V, Dunbar PR (2002) Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol 2: 263-272. doi: 10.1038/nri777. PubMed: 12001997.
63. Bullock TN, Colella TA, Engelhard VH (2000) The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J Immunol 164: 2354-2361. PubMed: 10679070.
64. Wherry EJ, McElhaugh MJ, Eisenlohr LC (2002) Generation of CD8(+) T cell memory in response to low, high, and excessive levels of epitope. J Immunol 168: 4455-4461. PubMed: 11970989.
65. Slyker JA, John-Stewart GC, Dong T, Lohman-Payne B, Reilly M et al. (2011) Phenotypic characterization of HIV-specific CD8+ T cells during early and chronic infant HIV-1 infection. PLOS ONE 6: e20375. doi: 10.1371/journal.pone. 0020375. PubMed: 21655252.
66. Goepfert PA, Bansal A, Edwards BH, Ritter GD Jr., Tellez I et al. (2000) A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol 74: 10249-10255. doi:10.1128/JVI.74.21.10249-10255.2000. PubMed: 11024158.
67. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T et al. (2000) HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 192: 63-75. doi:10.1084/jem.192.1.63. PubMed: 10880527.
68. van Baarle D, Hovenkamp E, Callan MF, Wolthers KC, Kostense S et al. (2001) Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 98: 146-155. doi:10.1182/blood.V98.1.146. PubMed: 11418474.
69. Sun Y, Iglesias E, Samri A, Kamkamidze G, Decoville T et al. (2003) A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods 272: 23-34. doi:10.1016/S0022-1759(02)00328-9. PubMed: 12505709.
70. Shankar P, Russo M, Harnisch B, Patterson M, Skolnik P et al. (2000) Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood 96: 3094-3101. PubMed: 11049989.
71. Kostense S, Ogg GS, Manting EH, Gillespie G, Joling J et al. (2001) High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur J Immunol 31: 677-686. doi:10.1002/1521-4141(200103)31:3. PubMed: 11241270.
72. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM et al. (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8: 379-385. doi:10.1038/nm0402-379. PubMed: 11927944.
73. Dolfi DV, Duttagupta PA, Boesteanu AC, Mueller YM, Oliai CH et al. (2011) Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo. J Immunol 186: 4599-4608. doi:10.4049/jimmunol.1001972. PubMed: 21389258.
74. Mitchell DM, Ravkov EV, Williams MA (2010) Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells. J Immunol 184: 6719-6730. doi:10.4049/jimmunol.0904089. PubMed: 20483725.
75. Sgadari C, Barillari G, Palladino C, Bellino S, Taddeo B et al. (2011) Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. Int J Vasc Med, 2011: 2011: 452729. PubMed: 22007303
76. Zauli G, Gibellini D, Celeghini C, Mischiati C, Bassini A et al. (1996) Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes. J Immunol 157: 2216-2224. PubMed: 8757349.
77. Westendorp MO, Li-Weber M, Frank RW, Krammer PH (1994) Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol 68: 4177-4185. PubMed: 8207793.
78. Williams MA, Tyznik AJ, Bevan MJ (2006) Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441: 890-893. doi:10.1038/nature04790. PubMed: 16778891.
79. Ladell K, Hellerstein MK, Cesar D, Busch R, Boban D et al. (2008) Central memory CD8+ T cells appear to have a shorter lifespan and reduced abundance as a function of HIV disease progression. J Immunol 180: 7907-7918. PubMed: 18523254.
80. Chen G, Shankar P, Lange C, Valdez H, Skolnik PR et al. (2001) CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood 98: 156-164. doi:10.1182/blood.V98.1.156. PubMed: 11418475.
81. Hayes PJ, Miao YM, Gotch FM, Gazzard BG (1999) Alterations in blood leucocyte adhesion molecule profiles in HIV-1 infection. Clin Exp Immunol 117: 331-334. doi:10.1046/j.1365-2249.1999.00983.x. PubMed: 10444267.
82. Lefevre EA, Krzysiek R, Loret EP, Galanaud P, Richard Y (1999) Cutting edge: HIV-1 Tat protein differentially modulates the B cell response of naive, memory, and germinal center B cells. J Immunol 163: 1119-1122. PubMed: 10415004.
83. Moir S, Fauci AS (2009) B cells in HIV infection and disease. Nat Rev Immunol 9: 235-245. doi:10.1038/nri2524. PubMed: 19319142.
84. Barron MA, Blyveis N, Palmer BE, MaWhinney S, Wilson CC (2003) Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis 187: 26-37. doi:10.1086/345957. PubMed: 12508143.
85. Dillon SM, Robertson KB, Pan SC, Mawhinney S, Meditz AL et al. (2008) Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J Acquir Immune Defic Syndr 48: 1-12. doi:10.1097/QAI.0b013e3181664b60. PubMed: 18300699.
86. Bachler BC, Humbert M, Palikuqi B, Siddappa NB, Lakhashe SK et al. (2013) Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol 87: 4403-4416. doi:10.1128/JVI.02888-12. PubMed: 23388727.
87. Caputo A, Gavioli R, Bellino S, Longo O, Tripiciano A et al. (2009) HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int Rev Immunol 28: 285-334. doi: 10.1080/ 08830180903013026. PubMed: 19811313.